Neuro-oncology
ON-01, an engineered recombinant oncolytic herpes simplex virus type-1, in recurrent glioma: a single-arm, phase 1/2 study.
Wei Zeng, Peiwen Wang, Sheng Fang, Siqi Ge, Weifeng Jia, Shirong Peng, Mengyang Wang, Xiaoyang Qin, Wenxin Zhang, Jiajia Gao, Xiaodong Su, Guiqiang Yuan, Jiankun Wu, Yida Liu, Youwen Wang
Published: 202610.1093/neuonc/noag005
Abstract
BACKGROUND: The prognosis of patients with recurrent WHO grade 4 glioma is poor, particularly in glioblastoma (GBM), which has a median survival of approximately 6 months and no effective treatment options. We evaluated the short-term (28-day) safety…
Preview only. Read the full abstract at the source